Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study.
Adolescent
Age Factors
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Central Nervous System Neoplasms
/ mortality
Chemoradiotherapy
/ adverse effects
Child
Child, Preschool
Cranial Irradiation
/ adverse effects
Disease Progression
Female
Humans
Male
Neoplasm Recurrence, Local
Neoplasms, Germ Cell and Embryonal
/ mortality
Progression-Free Survival
Radiation Dosage
Risk Factors
Time Factors
United States
Young Adult
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
01 12 2019
01 12 2019
Historique:
pubmed:
24
9
2019
medline:
23
6
2020
entrez:
24
9
2019
Statut:
ppublish
Résumé
Stratum 1 of ACNS1123 (ClinicalTrials.gov identifier: NCT01602666), a Children's Oncology Group phase II trial, evaluated efficacy of reduced-dose and volume of radiotherapy (RT) in children and adolescents with localized nongerminomatous germ cell tumors (NGGCTs). The primary objective was to evaluate the impact of reduced RT on progression-free survival (PFS) with a goal of preserving neurocognitive function. Patients received six cycles of chemotherapy with carboplatin and etoposide alternating with ifosfamide and etoposide, as used in the Children's Oncology Group predecessor study (ACNS0122; ClinicalTrials.gov identifier: NCT00047320). Patients who achieved a complete response (CR) or partial response (PR) with or without second-look surgery were eligible for reduced RT, defined as 30.6 Gy whole ventricular field and 54 Gy tumor-bed boost, compared with 36 Gy craniospinal irradiation plus 54 Gy tumor-bed boost used in ACNS0122. A total of 107 eligible patients were enrolled. Median age was 10.98 years (range, 3.68 to 21.63) and 75% were male. Sixty-six of 107 (61.7%) achieved a CR or PR and proceeded to reduced RT. The 3-year PFS and overall survival and standard error values were 87.8% ± 4.04% and 92.4% ± 3.3% compared with 92% and 94.1%, respectively, in ACNS0122. There were 10 recurrences, prompting early study closure; however, after a retrospective central review, only disease in eight of 66 (12.1%) patients eligible for reduced RT subsequently progressed; six patients had distant spinal relapse alone and two had disease with combined local plus distant relapse. Serum and CSF α-fetoprotein and β-human chorionic gonadotropin levels were not associated with PFS. Patients with localized NGGCT who achieved a CR or PR to chemotherapy and received reduced RT had encouraging PFS similar to patients in ACNS0122 who received full-dose craniospinal irradiation. However, the patterns of failure were distinct, with all patients having treatment failure in the spine.
Identifiants
pubmed: 31545689
doi: 10.1200/JCO.19.00701
pmc: PMC6900864
doi:
Banques de données
ClinicalTrials.gov
['NCT01602666', 'NCT00047320']
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3283-3290Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180886
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180899
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003167
Pays : United States
Références
Neuropediatrics. 1992 Oct;23(5):228-34
pubmed: 1454140
Neuro Oncol. 2012 Sep;14(9):1194-200
pubmed: 22869621
BMC Genomics. 2010 Feb 24;11:132
pubmed: 20178649
Neurology. 2007 May 15;68(20):1668-73
pubmed: 17502547
Oncologist. 2008 Jun;13(6):690-9
pubmed: 18586924
Neuro Oncol. 2001 Jul;3(3):174-83
pubmed: 11465398
Neuro Oncol. 2017 Nov 29;19(12):1661-1672
pubmed: 29048505
J Child Neurol. 2009 Nov;24(11):1439-45
pubmed: 19841431
Neuropediatrics. 1994 Feb;25(1):26-32
pubmed: 8208347
Pediatr Blood Cancer. 2004 Aug;43(2):126-33
pubmed: 15236278
J Clin Oncol. 1996 Nov;14(11):2908-15
pubmed: 8918487
J Clin Oncol. 2015 Aug 1;33(22):2464-71
pubmed: 26101244
Pediatr Blood Cancer. 2010 Mar;54(3):377-83
pubmed: 20063410
J Okla State Med Assoc. 2015 Apr;108(4):129-35
pubmed: 26263577
Pediatr Blood Cancer. 2012 Sep;59(3):536-9
pubmed: 22555997
Curr Neurol Neurosci Rep. 2004 May;4(3):253-62
pubmed: 15102352
Lancet Oncol. 2015 Sep;16(9):e470-e477
pubmed: 26370356